Disease · MONDO_0016262
Trials20
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
1 to 20 of 20
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03565991 | Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors | Phase 2 | 202 | 2023-08-07 | Locally Advanced or Metastatic Solid Tumors, Genes, BRCA 1 | AVELUMAB, TALAZOPARIB | Its record names the disease | ClinicalTrials.gov |
| NCT01012297 | Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma | Phase 3 | 107 | 2017-07-14 | Recurrent Uterine Corpus Sarcoma, Stage IIIA Uterine Sarcoma, Stage IIIB Uterine Sarcoma, Stage IIIC Uterine Sarcoma, Stage IVA Uterine Sarcoma, Stage IVB Uterine Sarcoma, Uterine Corpus Leiomyosarcoma | BEVACIZUMAB, DOCETAXEL, GEMCITABINE HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT01533207 | Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery | Phase 3 | 38 | 2020-04-06 | Stage I Uterine Sarcoma AJCC v7, Uterine Corpus Leiomyosarcoma | DOCETAXEL, DOXORUBICIN HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT00856050 | Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma | Phase 2 | 27 | 2014-03-19 | Leiomyosarcoma | LETROZOLE | Its record names the disease | ClinicalTrials.gov |
| NCT03880019 | A Phase II Clinical Trial Evaluating the Combination of Olaparib and Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma | Phase 2 | 23 | 2023-09-21 | Stage III Uterine Corpus Leiomyosarcoma AJCC v8, Stage IV Uterine Corpus Leiomyosarcoma AJCC v8, Uterine Corpus Leiomyosarcoma | OLAPARIB, TEMOZOLOMIDE | Its record names the disease | ClinicalTrials.gov |
| NCT00379145 | Trabectedin in Treating Patients With Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus | Phase 2 | 20 | 2017-12-12 | Sarcoma | TRABECTEDIN | Its record names the disease | ClinicalTrials.gov |
| NCT01958580 | Gemcitabine Hydrochloride, Docetaxel, and Radiation Therapy in Treating Patients With Uterine Sarcoma That Has Been Removed By Surgery | Not applicable | 3 | 2023-08-16 | Stage IA Uterine Sarcoma, Stage IB Uterine Sarcoma, Stage IC Uterine Sarcoma, Stage IIA Uterine Sarcoma, Stage IIB Uterine Sarcoma, Stage IIIA Uterine Sarcoma, Stage IIIB Uterine Sarcoma, Stage IIIC Uterine Sarcoma, Stage IVA Uterine Sarcoma, Stage IVB Uterine Sarcoma, Uterine Corpus Leiomyosarcoma | DOCETAXEL, GEMCITABINE HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT04969887 | Combination Immunotherapy in Rare Cancers Under InvesTigation | Phase 2 | 240 | Advanced Biliary Tract Cancer, Neuroendocrine Tumors, Female Reproductive System Neoplasm, MSI-H Solid Malignant Tumor | IPILIMUMAB, NIVOLUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT02249702 | Activity of Trabectedin or Gemcitabine + Docetaxel in Uterine Leiomyosarcoma | Phase 2 | 168 | Leiomyosarcoma | DOCETAXEL, GEMCITABINE, TRABECTEDIN | Its record names the disease | ClinicalTrials.gov | |
| NCT02131480 | Study of Doxorubicin and Trabectedin in First Line Treatment on Patients With Metastatic Leiomyosarcoma | Phase 2 | 110 | Uterus Leiomyosarcoma, Soft Tissue Leiomyosarcoma | DOXORUBICIN, TRABECTEDIN | Its record names the disease | ClinicalTrials.gov | |
| NCT00227669 | Gemcitabine With or Without Docetaxel as Second-Line Therapy in Treating Patients With Metastatic or Relapsed, Unresectable Uterine or Soft Tissue Leiomyosarcoma | Phase 2 | 90 | Sarcoma | DOCETAXEL, GEMCITABINE | Its record names the disease | ClinicalTrials.gov | |
| NCT05432791 | Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working | Phase 2/3 | 74 | Locally Advanced Uterine Corpus Leiomyosarcoma, Metastatic Uterine Corpus Leiomyosarcoma, Stage III Uterine Corpus Leiomyosarcoma AJCC v8, Stage IV Uterine Corpus Leiomyosarcoma AJCC v8, Unresectable Uterine Corpus Leiomyosarcoma | OLAPARIB, TEMOZOLOMIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT02203760 | Pazopanib Vs. Pazopanib Plus Gemcitabine | Phase 2 | 58 | Leiomyosarcoma or Carcinosarcoma | GEMCITABINE, PAZOPANIB | Its record names the disease | ClinicalTrials.gov | |
| NCT07076186 | Phase II Decentralized Pragmatic Trial of Adjuvant Doxorubicin - Trabectedin Chemotherapy in uLMS | Phase 2 | 48 | Uterine Leiomyosarcoma | DOXORUBICIN HYDROCHLORIDE, TRABECTEDIN | Its record names the disease | ClinicalTrials.gov | |
| NCT00378911 | Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus | Phase 2 | 44 | Recurrent Uterine Sarcoma, Uterine Leiomyosarcoma | SUNITINIB MALATE | Its record names the disease | ClinicalTrials.gov | |
| NCT05649956 | Letrozole in Uterine Leiomyosarcoma | Phase 2 | 40 | Uterine Leiomyosarcoma | LETROZOLE | Its record names the disease | ClinicalTrials.gov | |
| NCT00002993 | Combination Chemotherapy in Treating Patients With Recurrent or Advanced Cancer of the Uterus | Phase 2 | 30 | Sarcoma | CISPLATIN, DOXORUBICIN, MITOMYCIN | Its record names the disease | ClinicalTrials.gov | |
| NCT02066675 | Trabectedin First Line Therapy In Unfit Sarcoma Study | Phase 2 | 24 | Metastatic and Locally Advanced Soft Tissue Tumor Patients Unfit to Receive, Standard Chemotherapy | TRABECTEDIN | Its record names the disease | ClinicalTrials.gov | |
| NCT04727242 | CytoreductiveSurgery & HIPEC w/Gemcitabine+Chemotherapy w/Dacarbazine in Uterine Leiomyosarcoma | Phase 2 | 17 | LMS - Leiomyosarcoma, Uterine Leiomyosarcoma | DACARBAZINE, GEMCITABINE | Its record names the disease | ClinicalTrials.gov | |
| NCT00101127 | Docetaxel, Gemcitabine, and Filgrastim (G-CSF) or Pegfilgrastim in Treating Patients With Advanced, Persistent, or Recurrent Uterine Leiomyosarcoma | Phase 2 | Sarcoma | DOCETAXEL, FILGRASTIM, GEMCITABINE HYDROCHLORIDE, PEGFILGRASTIM | Its record names the disease | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0016262/trials